Summary
The Finland Herceptin [FinHer] trial results and concerns about cardiac toxicity with trastuzumab provided the rationale for the Trastuzumab for 6 Months or 1 Year in Treating Women with Nonmetastatic Breast Cancer That Can Be Removed by Surgery [PHARE; NCT00381901] trial. The primary objective of this noninferiority trial was to compare the effect of 6 versus 12 months of adjuvant treatment with trastuzumab on disease-free survival in patients with HER2-positive early breast cancer.
- Adjuvant/Neoadjuvant Therapy
- Oncology Clinical Trials
- Breast Cancer
- © 2012 MD Conference Express®
Tools
Adjuvant Trastuzumab for 6 versus 12 Months in Patients with Early Breast Cancer
Permalink:
Table of contents
Cited By...
- No citing articles found.